Cocrystals of spironolactone and griseofulvin based on an in silico screening method

Cocrystal formation is considered as one of the most effective solid-state methods to alter the physicochemical properties of active pharmaceutical ingredients (APIs). In silico methods for cocrystal prediction are mostly based on structural and energetic considerations. We have developed a computational method that ranks the probability of cocrystal formation of APIs with large databases of crystal coformers (CCFs). This approach is based on using molecular electrostatic potential surfaces to assess molecular complementarity between two cocrystal components. The screening tool was applied to two low solubility drugs, namely griseofulvin and spironolactone. Promising coformer candidates were selected from a database of 310 pharmaceutically acceptable CCFs, and experimental screening was carried out. Novel solid forms were obtained by liquid-assisted grinding and were characterised by XRPD, DSC, TGA and IR. One new cocrystal of griseofulvin and two new cocrystals of spironolactone were identified, and the crystal structures were determined from the XRPD patterns. For these systems, phenols tend to act as successful H-bond donors in forming cocrystals, while carboxylic acids only give rise to physical mixtures of the two components.

[1]  T. O. Larsen,et al.  The chemistry of griseofulvin. , 2014, Chemical reviews.

[2]  Jun Xu,et al.  Co-crystal formation between poly(ethylene glycol) and a small molecular drug griseofulvin. , 2014, Chemical communications.

[3]  C. Hunter,et al.  Virtual Screening Identifies New Cocrystals of Nalidixic Acid , 2014 .

[4]  R. Tan,et al.  Solvates of the antifungal drug griseofulvin: structural, thermochemical and conformational analysis. , 2014, Acta crystallographica Section B, Structural science, crystal engineering and materials.

[5]  Eleanor J. Gardiner,et al.  Validation of a Computational Cocrystal Prediction Tool: Comparison of Virtual and Experimental Cocrystal Screening Results , 2014 .

[6]  Eleanor J. Gardiner,et al.  Footprinting molecular electrostatic potential surfaces for calculation of solvation energies. , 2013, Physical chemistry chemical physics : PCCP.

[7]  C. Hunter A surface site interaction model for the properties of liquids at equilibrium , 2013 .

[8]  Changquan Calvin Sun,et al.  Cocrystallization for successful drug delivery , 2013, Expert opinion on drug delivery.

[9]  R. Tan,et al.  Cocrystal Hydrate of an Antifungal Drug, Griseofulvin, with Promising Physicochemical Properties , 2012 .

[10]  Y. Ikeda,et al.  Establishment of cocrystal cocktail grinding method for rational screening of pharmaceutical cocrystals. , 2012, International journal of pharmaceutics.

[11]  C. Tang,et al.  Fast X-ray powder diffraction on I11 at Diamond. , 2011, Journal of synchrotron radiation.

[12]  Christopher A. Hunter,et al.  Virtual cocrystal screening , 2011 .

[13]  Naír Rodríguez-Hornedo,et al.  Dependence of cocrystal formation and thermodynamic stability on moisture sorption by amorphous polymer , 2011 .

[14]  R. Sinclair,et al.  Use of spironolactone in dermatology. , 2010, Skinmed.

[15]  R. Hilfiker,et al.  Cocrystal Formation from Solvent Mixtures , 2010 .

[16]  K. Terada,et al.  A Spironolactone−Saccharin 1:1 Cocrystal Hemihydrate , 2010 .

[17]  J. Parker,et al.  Beamline I11 at Diamond: a new instrument for high resolution powder diffraction. , 2009, The Review of scientific instruments.

[18]  A. Newman,et al.  Pharmaceutical Cocrystals and Their Physicochemical Properties , 2009, Crystal growth & design.

[19]  William Jones,et al.  Recent Advances in Understanding the Mechanism of Cocrystal Formation via Grinding , 2009 .

[20]  A. Bak,et al.  Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals , 2008 .

[21]  B. Sarmento,et al.  Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. , 2007, Drug discovery today.

[22]  Andrew D. Bond,et al.  What is a co-crystal? , 2007 .

[23]  Manfred Kansy,et al.  High throughput solubility measurement in drug discovery and development. , 2007, Advanced drug delivery reviews.

[24]  L. Fábián,et al.  Powder X-ray diffraction as an emerging method to structurally characterize organic solids. , 2007, Organic letters.

[25]  G. P. Stahly Diversity in Single- and Multiple-Component Crystals. The Search for and Prevalence of Polymorphs and Cocrystals , 2007 .

[26]  Dominique Duchêne,et al.  Cyclodextrins and their pharmaceutical applications. , 2007, International journal of pharmaceutics.

[27]  W. Motherwell,et al.  Physical stability enhancement of theophylline via cocrystallization. , 2006, International journal of pharmaceutics.

[28]  Peddy Vishweshwar,et al.  Pharmaceutical co-crystals. , 2006, Journal of pharmaceutical sciences.

[29]  Sarah J. Nehm,et al.  Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation , 2006 .

[30]  Zili Zhang,et al.  Preparation and characterization of poly-?-caprolactone nanoparticles containing griseofulvin , 2005 .

[31]  Alan R. Kennedy,et al.  Solving molecular crystal structures from laboratory X-ray powder diffraction data with DASH: the state of the art and challenges , 2005 .

[32]  G Vergnault,et al.  Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound , 2005, Drug development and industrial pharmacy.

[33]  Michael J Cima,et al.  High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.

[34]  M. Gallarate,et al.  Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. , 2003, International journal of pharmaceutics.

[35]  Michael J. Zaworotko,et al.  Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? , 2003, Chemical communications.

[36]  V. Favre-Nicolin,et al.  FOX, `free objects for crystallography': a modular approach to ab initio structure determination from powder diffraction , 2002 .

[37]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[38]  Bruno C. Hancock,et al.  What is the True Solubility Advantage for Amorphous Pharmaceuticals? , 2000, Pharmaceutical Research.

[39]  Chaumeil Jc Micronization: a method of improving the bioavailability of poorly soluble drugs. , 1998 .

[40]  M. Aldén,et al.  Phase equilibria in drug-polymer-surfactant systems , 1995 .

[41]  Juan Rodríguez-Carvajal,et al.  Recent advances in magnetic structure determination by neutron powder diffraction , 1993 .

[42]  D. Louër,et al.  Indexing of powder diffraction patterns for low-symmetry lattices by the successive dichotomy method , 1991 .

[43]  M. C. Etter Encoding and decoding hydrogen-bond patterns of organic compounds , 1990 .

[44]  G. S. Pawley,et al.  Unit-cell refinement from powder diffraction scans , 1981 .

[45]  J. Haleblian,et al.  Characterization of habits and crystalline modification of solids and their pharmaceutical applications. , 1975, Journal of pharmaceutical sciences.

[46]  H. Rietveld A profile refinement method for nuclear and magnetic structures , 1969 .

[47]  R. Lewis,et al.  Hawley ' s Condensed Chemical Dictionary , 2017 .

[48]  K. Terada,et al.  Stability order of caffeine co-crystals determined by co-crystal former exchange reaction and its application for the validation of in silico models. , 2015, Chemical and pharmaceutical bulletin.